Peptide Library

Human study PLS-00136

Longitudinal Trends of Salivary Oxidized Thymosin β4 and β10 in Preterm Infants with Bronchopulmonary Dysplasia.

Other design · 18 participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Longitudinal Trends of Salivary Oxidized Thymosin β4 and β10 in Preterm Infants with Bronchopulmonary Dysplasia.primary · Children (Basel, Switzerland) · 2026-06-02 · PMID 42353940 · DOI

Design and participants

Design
Other design
Population
Extremely preterm infants, some of whom developed bronchopulmonary dysplasia, with 149 saliva samples collected longitudinally. The gestational age cutoff is truncated in the abstract.
Conditions
Bronchopulmonary dysplasia, Prematurity
Planned enrollment (registry)
Not reported
Enrolled
18
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): No early differences were found, but longitudinal trajectories of salivary Tβ4 and Tβ10 differed between infants with and without BPD. Postnatal changes may relate to clinical course and oxidative stress exposure.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin β4 was only measured as an endogenous salivary biomarker and was never given as a treatment, so the study offers no evidence on its effects.
    • small or imprecise: Only 18 infants were included, per the abstract methods.
    • abstract only: Only a truncated abstract is available; methods and results are incomplete.
    • inappropriate endpoint: Endogenous salivary protein levels were measured as biomarkers; no compound was given, so there is no intervention effect to assess.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 42353940, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 42353940, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 42353940, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 42353940, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 42353940, title (title) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).